猫中等或大细胞淋巴瘤10周COP协议治疗结果:27例 (2014-2023)
M M E Larsen1, A-M Andersson2, M Arendt3
1Evidensia Specialist Animal Hospital in Helsingborg, Helsingborg, Sweden.
The Journal of small animal practice
|August 8, 2024
概括
10周的无维护COP (COP-10) 协议显示,对猫类淋巴瘤的有效治疗,实现良好的缓解率和持久的生存时间,与较长的协议相比.
科学领域:
- 兽医瘤学 兽医瘤学
- 猫科动物医学 猫科动物医学
背景情况:
- 淋巴瘤是猫的一种常见癌症.
- 治疗方案在持续时间和疗效方面有所不同.
- 评估更短,有效的化疗方案对于猫的生活质量和所有者遵守至关重要.
研究的目的:
- 评估中等或大细胞淋巴瘤猫的10周无维护COP (COP-10) 协议的治疗反应.
- 为了确定影响治疗结果的预后因素在这种猫科动物队列.
主要方法:
- 2014-2023年医疗记录的回顾性审查.
- 纳入标准:患有中等或大细胞淋巴瘤的猫,接受COP-10作为一线治疗.
- 数据分析的重点是响应率,无进展间隔和生存时间.
主要成果:
- 分析了27只猫,平均年龄为10岁.
- 总体应答率为65% (38%完全缓解,27%部分缓解).
- 完全缓解与中位数无进展间隔和1,139天的存活率相关;部分缓解的间隔较短.
- 临床阶段显著影响治疗反应和存活率.
结论:
- 根据COP-10协议,可以实现缓解率和持久的首次缓解,与猫的更长的化疗方案相比.
- 这种较短的协议可能为业主提供经济和后勤利益,可能改善猫咪的生活质量.
更多相关视频
06:32Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats
Published on: October 24, 2016
26.5K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...